Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
1980 1940 1950.5 1951 1957.5 Last
3012600 3017800 2148300 3556100 2690800 Volume
-1.10% -2.02% +0.54% +0.03% +0.33% Change
Estimated financial data (e)
Sales 2022 1 327 B 11 688 M 11 688 M
Net income 2022 196 B 1 723 M 1 723 M
Net cash position 2022 584 B 5 142 M 5 142 M
P/E ratio 2022 18,4x
Yield 2022 2,55%
Sales 2023 1 403 B 12 359 M 12 359 M
Net income 2023 233 B 2 054 M 2 054 M
Net cash position 2023 745 B 6 566 M 6 566 M
P/E ratio 2023 15,3x
Yield 2023 2,82%
Capitalization 3 627 B 31 899 M 31 957 M
EV / Sales 2022 2,29x
EV / Sales 2023 2,05x
Nbr of Employees 15 455
Free-Float 98,9%
More Financials
Company
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others. 
Sector
Pharmaceuticals
Calendar
10/29Earnings Release
More about the company
Ratings of Astellas Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about ASTELLAS PHARMA INC.
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
09/30ASTELLAS PHARMA : announces the publication of New Contents related to its Corporate Strat..
PU
09/29ASTELLAS PHARMA : Recognized Consistently Among Top Companies for Working Parents
AQ
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/28ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
AQ
More news
News in other languages on ASTELLAS PHARMA INC.
10/12Seagen et Astellas achèvent le recrutement de la Cohorte K de l'étude sur l'association..
10/05MIG Fonds führt 65 Mio. EUR Serie-B-Finanzierung von iOmx Therapeutics an
10/04MIG verkauft Beteiligung an Hemovent GmbH an MicroPort
09/27Padcev, le médicament de Seagen contre le cancer urothélial, obtient l'approbation de l..
08/17GlobeNewswire/Basilea meldet starke Finanzergebnisse für das erste Halbjahr 2021 mit de..
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 957,50 JPY
Average target price 2 486,15 JPY
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.22.80%31 899
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979